SBFM
Sunshine Biopharma Inc
NASDAQ: SBFM · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.03
-3.38% today
Updated 2026-06-04
Market cap
$4.33M
P/E ratio
—
P/S ratio
0.12x
EPS (TTM)
$-12.50
Dividend yield
—
52W range
$2 – $24
Volume
16.8M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+7.0
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$56.00
+5336.89%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Altman Z 0.00 — distress zone
- Thin margins at -17.00%
- Negative free cash flow $-2.08M
- Revenue declining -9.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $4.35M | $24.09M | $34.87M | $36.31M | $35.49M |
| Net income | $-26.74M | $-4.51M | $-5.13M | $-5.98M | $-1.24M |
| EPS | — | — | — | — | $-12.50 |
| Free cash flow | $-5.55M | $-9.56M | $-14.85M | $-5.51M | $-2.08M |
| Profit margin | -615.44% | -18.70% | -14.72% | -16.46% | -17.00% |
Peer comparison
Smart narrative
Sunshine Biopharma Inc trades at $1.03. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $35.49M. with profit margins at -17.00%.
Frequently asked questions
What is Sunshine Biopharma Inc's stock price?
Sunshine Biopharma Inc (SBFM) trades at $1.03, on a P/S of 0.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sunshine Biopharma Inc overvalued?
Sunshine Biopharma Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Sunshine Biopharma Inc (SBFM)?
The 12-month analyst consensus target is $56.00, about 5336.9% above the current $1.03. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Sunshine Biopharma Inc's revenue?
Sunshine Biopharma Inc's trailing twelve-month revenue is $35.49M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.12x
ROE-27.30%
Beta1.49
50D MA$7.91
200D MA$12.52
Shares out0.00B
Float0.00B
Short ratio—
Avg volume16.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—